Pages that link to "Q38013957"

The following pages link to Sarah-Jane Dawson (Q38013957):

Displaying 49 items.

• The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (Q28275430) (← links)
• Analysis of circulating tumor DNA to monitor metastatic breast cancer (Q29614797) (← links)
• Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA (Q29620083) (← links)
• Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data (Q30779447) (← links)
• Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies (Q33593016) (← links)
• Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression (Q34158093) (← links)
• Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. (Q34278191) (← links)
• Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer (Q34500359) (← links)
• Common breast cancer susceptibility loci are associated with triple-negative breast cancer (Q35891162) (← links)
• The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". (Q36233893) (← links)
• Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium (Q36873786) (← links)
• Triple negative breast cancers: clinical and prognostic implications. (Q37602289) (← links)
• Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? (Q38261856) (← links)
• Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. (Q38426753) (← links)
• BET inhibitor resistance emerges from leukaemia stem cells (Q38835493) (← links)
• Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes (Q38996488) (← links)
• Large B-cell lymphoma: is the future written in the blood? (Q39021647) (← links)
• Functional interdependence of BRD4 and DOT1L in MLL leukemia (Q39688289) (← links)
• Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma (Q40101923) (← links)
• Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes (Q42737815) (← links)
• Hypocalcemia associated with bone metastases in a patient with salivary-gland carcinoma. (Q46931442) (← links)
• The Value of Cell-free DNA for Molecular Pathology (Q48143437) (← links)
• Click chemistry enables preclinical evaluation of targeted epigenetic therapies. (Q48270517) (← links)
• A community-based model of rapid autopsy in end-stage cancer patients (Q48360452) (← links)
• Images in clinical medicine. Cerebral metastases in breast cancer. (Q48723478) (← links)
• Circulating Tumor DNA Guides Prognosis in Metastatic Triple-Negative Breast Cancer (Q49342704) (← links)
• Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer. (Q51054233) (← links)
• Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. (Q54255586) (← links)
• (Q55426619) (redirect page) (← links)
• Molecular biomarkers in breast cancer (Q56491631) (← links)
• Wet or Dry? Do Liquid Biopsy Techniques Compete with or Complement PET for Disease Monitoring in Oncology? (Q57990755) (← links)
• Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients (Q58702496) (← links)
• A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer (Q60685892) (← links)
• Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma (Q60685897) (← links)
• Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. (Q64951709) (← links)
• Characterizing the Cancer Genome in Blood (Q88910044) (← links)
• A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer (Q90286274) (← links)
• Selective targeting of BD1 and BD2 of the BET proteins in cancer and immuno-inflammation (Q90470435) (← links)
• Circulating tumor DNA for disease monitoring in the era of CAR T-cell therapy (Q91035170) (← links)
• The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper (Q91645050) (← links)
• Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial (Q92309770) (← links)
• Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors (Q93161423) (← links)
• Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma (Q93223071) (← links)
• Combining liquid biopsies and PET-CT for early cancer detection (Q96816198) (← links)
• Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study (Q100406813) (← links)
• Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy (Q100693227) (← links)
• Detection of cell-free microbial DNA using a contaminant-controlled analysis framework (Q112611222) (← links)
• Multi-omic machine learning predictor of breast cancer therapy response (Q112709172) (← links)
• Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death (Q114872739) (← links)